The Impact of GLP-1 Agonist and GIP Agonist on Bowel Preparation Quality: A Randomized Controlled Trial
The Cleveland Clinic
Summary
The goal of this clinical trial is to learn how GLP-1 and GIP agonists effect bowel preparation in patients scheduled for colonoscopies. The main questions it aims to answer are: * Does GLP-1 and GIP agonist increase the rate of inadequate bowel preparation? * Does the quality of bowel preparation differ in patients who hold vs. those who continue a single dose of their GLP-1 or GIP agonist medication? * Are there any differences in the rates of complications gastric aspiration in patients who hold vs. continue a single dose of their GLP-1 or GIP agonist medication?
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- Yes
Inclusion Criteria: * Adult patient (Age 18 years or older) * Patient scheduled for outpatient screening, surveillance, or diagnostic colonoscopy * Using a GLP-1 or GIP agonist at a stable dose for at least one month Exclusion Criteria: * Unable to provide informed consent, e.g., dementia * Patient refuses the USMSTF recommended bowel cleansing regimen for patients with diabetes or obesity (split-dose 4 liters polyethylene glycol + 15 mg bisacodyl the afternoon before; low residue diet 3 days before colonoscopy; clear liquid diet the day before colonoscopy) * Risk factors for inadequate bow…
Interventions
- DrugContinue GLP/GIP
Continue GLP-1 or GIP-based therapy as prescribed prior to the procedure.
Locations (3)
- Cleveland ClinicCleveland, Florida
- Cleveland ClinicCleveland, Florida
- Cleveland Clinic WestonWeston, Florida